2 Summary 25 Inducing β -cell proliferation could inhibit diabetes progression. Many factors have been 26 suggested as potential β -cell mitogens, but their impact on β -cell replication has not been 27 confirmed due to the lack of a standardized β -cell proliferation assay. In this study, we 28 developed a novel method that specifically labels replicating β cells and yields more 29 reproducible results than current immunohistochemical assays. We established a mouse line techniques. Replicating non-β cells within islets may also confound immunohistochemical 51 analyses. Furthermore, there are presently no alternative methods that can be used to resolve 52 these discrepant findings. Thus, new methods for quantifying replicating β cells are required 53 in order to validate the effects of potential β -cell mitogens. 54 The fluorescent ubiquitination-based cell cycle indicator (Fucci) reporter is a well-55 known probe for monitoring cell cycle status (Sakaue-Sawano et al., 2008 R26-Fucci2aR mice, we generated the RIP-Cre;Fucci2aR line in which the Fucci2a probe is 80 specifically expressed in β cells ( Fig. 1A ). RIP-Cre;Fucci2aR mice showed similar body 81 weight and arbitrary blood glucose levels compared to Fucci2aR littermates ( Fig. 1B and 1C ), 82 and there was no significant difference in blood glucose and insulin levels during in the oral 83 glucose tolerance test (2 g/kg) between them ( Fig. 1D and 1E Cre;Fucci2aR mice, mCherry and mVenus were expressed specifically in insulin + and Nkx 95 6.1 + cells (Figure 2A and 2D), but not in glucagon + or somatostatin + cells ( Figure 2B and 96 2C). To ensure that replicating β cells could be quantified, we compared the results of the 97 EdU assay and the β -cell proliferation assay performed using RIP-Cre;Fucci2aR mice. 98 Vehicle-and S961-treated mice were administered EdU 6 h before sacrifice, and mVenus + 99 5 cells ( Figure 2E ) or EdU + insulin + DAPI + cells ( Figure 2F ) were counted in frozen sections. 100 We found that the value of mVenus + cells per β cells tended to be higher than that of EdU + 101 insulin + cells per β cells. 
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The number of replicating β cells per islet is positively correlated with islet size 125 The relationship between the number of replicating β cells per islet and the 126 morphological characteristics of islets is unclear. We address this issue by analyzing 3D 127 images obtained from RIP-Cre;Fucci2aR mice. Blood glucose and insulin levels were higher 128 in mice treated with S961 (N = 4) than in those treated with vehicle (N = 4) ( Figure 4A, 4B ).
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When we examined all islets whose β -cell cluster diameter was over 100 µm, the β -cell was higher in the S961 + control than in the S961 + 0.02% empagliflozin group, the level in 158 the latter was similar to that in the vehicle + control group ( Figure 6A ). The S961 + 0.02% 159 empagliflozin group had a lower insulin level than the S961 + control group but nonetheless 160 showed hyperinsulinemia ( Figure 6B ), reflecting the continuous pharmacological action of 161 S961 irrespective of empagliflozin co-administration. 162 We next investigated the morphological characteristics of islets in all four groups and 163 found that islets were larger in mice treated with S961 as compared to vehicle ( Figure 6C 
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